BioNTech
Mainz · Founded 2008
About BioNTech
BioNTech is a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. It contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates.
Company Facts
- Founded: 2008
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 5,001 – 10,000
- Estimated revenue: $1M – $10M
- Total funding: $2.0B
- Funding stage: IPO
- Last round: Post-IPO Debt (Oct 2025)
- Ticker: nasdaq:BNTX
- Website: biontech.comintenhome.html
- Phone: +49 6131 9084-0
Industries & Categories
Biopharma, Biotechnology, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/biontech-74930 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.